通化东宝(600867)11月25日召开2025年第三季度业绩说明会，公司针对2025年第三季度的经营成果及财 务指标的具体情况与投资者进行交流。 通化东宝深耕糖尿病及内分泌代谢疾病领域，拥有以胰岛素为核心的产品体系，并为患者提供糖尿病治 疗的整体化方案。 公司在建立全面丰富的糖尿病治疗产品研发管线体系的基础上，不断扩大在研产品适应症覆盖范围，从 糖尿病延伸至减肥、非酒精性脂肪肝炎（NASH）等适应症，并拓展包括痛风和高尿酸血症在内的其他 内分泌代谢疾病治疗领域。 前三季度，公司实现营业收入21.8亿元，同比增长50.55%；实现净利润12.02亿元，上年同期为-6637万 元。其中，第三季度，实现营业收入8.06亿元，同比增长13.9%；净利润为9.84亿元，同比增长 499.86%。 （FDA）受理，后续将继续推进甘精胰岛素和赖脯胰岛素的BLA申报工作，并有序开展胰岛素类似物在 欧洲和"一带一路"共建国家的注册资料准备及申请工作。 GLP-1方面，公司与科兴制药合作开拓利拉鲁肽注射液海外市场，已通过埃及卫生部GMP现场审计并获 得哥伦比亚GMP证书，同时稳步开展其他新兴市场国家的注册与申报。 未来，公司将 ...

Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093), highlighting improvements in the company's prescription drug business and strong growth in respiratory and cardiovascular sectors [1] Performance Summary - For the first three quarters of 2025, the company reported revenue of 19.891 billion yuan, a year-over-year decrease of 12.3%, and a net profit attributable to shareholders of 3.511 billion yuan, down 7.1% year-over-year. Adjusted net profit was 3.079 billion yuan, a decline of 23.0% year-over-year, aligning with CICC's expectations. In Q3 2025, revenue reached 6.618 billion yuan, showing a year-over-year increase of 3.4% and a quarter-over-quarter increase of 5.7%, indicating stabilization in performance. The prescription drug revenue in Q3 2025 was 5.202 billion yuan, with year-over-year growth of 1.6% and quarter-over-quarter growth of 9.6% [2] Business Segment Performance - In Q3 2025, revenue from various therapeutic areas included: - Neurological diseases: 1.914 billion yuan (YoY -4.2%) - Oncology: 594 million yuan (YoY -47.2%) - Anti-infection: 826 million yuan (YoY -8.6%) - Cardiovascular diseases: 474 million yuan (YoY +17.8%) - Respiratory diseases: 320 million yuan (YoY +72.7%) - Digestive system: 248 million yuan (YoY +13.7%) - Other areas: 362 million yuan (YoY +25.6%) - The company’s raw material drug revenue was 1.415 billion yuan, with a year-over-year increase of 10.5% and a quarter-over-quarter decrease of 6.4% [2] R&D Progress - The company is advancing its innovation-driven strategy, with significant progress in its small nucleic acid pipeline. Key projects include PCSK9, expected to enter Phase III by the end of 2025, and other clinical projects targeting chronic diseases such as blood lipid and blood pressure management. The company is also exploring targeted delivery for eye, lung, fat, and muscle diseases. Notable in-development products include anti-HER2 monoclonal antibodies and EGFR ADCs [3] Overseas Business Development - The company is enhancing its business development strategy and has established an international licensing platform. In the first three quarters of 2025, it achieved licensing revenue of 1.540 billion yuan. In Q3 2025, the company licensed SYH2086 (an oral small molecule GLP-1) to Madrigal Pharmaceuticals for global development and commercialization outside of China, which includes an upfront payment of 120 million USD and potential milestone payments of up to 1.955 billion USD, along with double-digit sales royalties. The company has additional innovative products in its pipeline that are expected to lead to further licensing opportunities and milestone revenue recognition [4] Profit Forecast and Valuation - Considering increased R&D investments, CICC has lowered its net profit forecasts for 2025 and 2026 by 12% and 15% to 4.760 billion yuan and 5.353 billion yuan, respectively. The current stock price corresponds to a price-to-earnings ratio of 17.1 times for 2025 and 15.0 times for 2026. The "outperform" rating is maintained, with a target price reduction of 15% to 11.00 HKD, reflecting a price-to-earnings ratio of 24.4 times and 21.4 times for 2025 and 2026, respectively, indicating a potential upside of 42.5% [5]

Core Insights - The China International Import Expo (CIIE) has seen consistent participation from 170 overseas companies and 27 institutions over its eight-year history, showcasing the growing commitment of international firms to the Chinese market [1] - The expo serves as a platform for companies to transform exhibits into products, enhancing their market presence and fostering innovation [2][3] - CIIE is recognized as a bridge for global businesses to enter the Chinese market while also facilitating the export of Chinese goods [4][5] Group 1: Company Participation and Growth - Amorepacific showcased nearly 300 products, including over 20 new launches exclusive to China, indicating a strong commitment to the Chinese market [2] - Lesaffre has experienced significant growth in investment and business performance in China, leveraging the expo for collaborative agreements across various sectors [2] - Emerson has established 15 manufacturing bases and 8 R&D centers in China, emphasizing local product development that supports both domestic and global markets [3] Group 2: Innovation and Development - The CIIE has activated innovation, positioning China as a global testing ground for new ideas and applications, thereby boosting multinational companies' confidence in the market [2][3] - Toyota and Pony.ai introduced a mass-production version of their autonomous vehicle at the expo, highlighting the collaboration between foreign brands and local innovation [3] - Volkswagen continues to deepen its investment in local R&D, collaborating with domestic partners to enhance technological capabilities [3] Group 3: Market Opportunities and Global Sharing - CIIE is described as a global public good that shares development opportunities, aiding foreign companies in entering the Chinese market while promoting Chinese exports [4][5] - L'Oréal's participation reflects a strong belief in the Chinese market, with plans for future involvement in upcoming expos [4] - Charoen Pokphand Group introduced 231 products at the expo, including new offerings from Thailand, showcasing its role in enriching consumer choices in China [5]

Core Viewpoint - Asia-Pacific Pharmaceutical (亚太药业) faced a setback as its application for the consistency evaluation of Diltiazem Hydrochloride Tablets was rejected by the National Medical Products Administration (NMPA) just a month after a significant change in its controlling shareholder and a capital increase plan [1][2][4]. Group 1: Company Overview - Asia-Pacific Pharmaceutical was established in 1989 and primarily produces chemical generic drugs, with over 60% of its products being antibiotics [3]. - The company has been experiencing a decline in performance for six consecutive years, with a cumulative loss exceeding 2.5 billion yuan in net profit excluding non-recurring items from 2019 to 2024 [3][4]. Group 2: Financial Performance - In the first half of 2025, the company reported revenue of 152 million yuan, a year-on-year decrease of 31.48%, while the net profit attributable to shareholders increased by 1820.97% due to the sale of a subsidiary [3]. - The third-quarter report for 2025 indicated a net profit of 97.2 million yuan, a year-on-year increase of 2909.49%, but the net profit excluding non-recurring items showed a loss of 56.6 million yuan, reflecting a 150.47% increase in loss [4]. Group 3: Market Challenges - The company’s product structure, heavily reliant on chemical generics, faces intense market competition and challenges due to delays in the consistency evaluation of generics, leading to weakened competitiveness [4]. - As of now, only 19 of the company's products have passed the consistency evaluation, and the ongoing pressures from normalized centralized procurement and slowing demand for antibiotics have resulted in declining sales and prices [4]. Group 4: Strategic Shift - In October 2023, Starry Holdings acquired 14.62% of Asia-Pacific Pharmaceutical for 900 million yuan, marking a 45.68% premium, and initiated a 700 million yuan capital increase plan aimed at transitioning the company from generic to innovative drug development [4]. - The recent failure of the consistency evaluation for Diltiazem Hydrochloride Tablets poses a significant challenge to this strategic shift towards innovation [4].

Core Insights - The company reported a robust revenue growth of 28% year-on-year for the first three quarters of 2025, with total revenue reaching 21 billion [1] - The net profit attributable to shareholders increased by 31% to 1.933 billion, while the non-recurring net profit grew by 14% to 1.48 billion [1] Financial Performance - For Q3 2025, the company achieved a revenue of 8.15 billion, marking a 20% increase year-on-year, with a net profit of 766 million, up 28% [1] - The gross profit margin improved to 44.6% in Q3 2025, an increase of 1.6 percentage points compared to the previous year [2] - The sales net profit margin for Q3 2025 was 9.9%, reflecting a 0.7 percentage point increase year-on-year [2] Product Innovation - The company launched several new products in Q3 2025, including the Anker Prime series and a new generation of home energy systems at the IFA exhibition [3] - The introduction of the world's first AI-powered security camera and various smart cleaning products demonstrates the company's commitment to innovation [3] - New audio products, such as a coin-sized AI smart recording device, were also unveiled, showcasing the company's expansion in the smart audio segment [3] Market Outlook - The company is positioned as a benchmark for Chinese consumer electronics brands going global, with a stable increase in independent site revenue [4] - Revenue projections for 2025-2027 are estimated at 32.2 billion, 40.3 billion, and 49.3 billion respectively, with expected growth rates of 30%, 25%, and 22% [4] - The net profit forecast for the same period is 2.71 billion, 3.31 billion, and 4.26 billion, with corresponding growth rates of 28%, 22%, and 29% [4]

Core Insights - The company reported a significant increase in revenue for the first three quarters of 2025, achieving 208 million yuan, a year-on-year increase of 1562.05% [1] - In Q3 alone, the revenue reached 162 million yuan, marking a year-on-year growth of 1199.88% [1] - The primary drivers of this growth were the sales of the company's first commercial product, Saliqi monoclonal antibody injection (Jinlixi), and the recognition of licensing income from the GR1803 injection's commercialization agreement [1] Revenue and Financial Performance - The overall revenue increase led to a substantial narrowing of the company's losses [1] - The company reported R&D expenditures of approximately 130 million yuan in Q3, with total R&D investments reaching 349 million yuan for the first three quarters [2] Product Development and Clinical Trials - Multiple ongoing projects made significant progress during the reporting period, including the approval and initiation of clinical trials for various products [1][2] - In July, the clinical trial application for Sileweimi monoclonal antibody injection for passive immunity in children and adolescents exposed to suspected rabies virus was approved [1] - In August, clinical trial applications for GR1802 monoclonal antibody injection for seasonal allergic rhinitis in adults and adolescents were approved [1] - In September, clinical trial applications for GR2303 injection for inflammatory bowel disease, GR1803 injection for systemic lupus erythematosus, and GR2301 injection for vitiligo were approved [2] - The new drug application for GR1802 injection for moderate to severe atopic dermatitis was accepted [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported a revenue of 391 million yuan for the first three quarters of 2025, representing a year-on-year increase of 17.65%, and a net profit attributable to shareholders of 62 million yuan, up 623.19% [6] - The company's core growth driver, the Shuimu Tianpeng product line, continues to show rapid growth, with a revenue of 115 million yuan in the first three quarters, an increase of 52.21% [7] - The international business, particularly in the U.S. market, has become a significant growth engine, with overseas revenue reaching over 18 million yuan, nearly doubling year-on-year [7] Financial Performance Summary - For the first three quarters of 2025, the company achieved a revenue of 391 million yuan (+17.65%) and a net profit of 62 million yuan (+623.19%) [6] - The third quarter alone saw a revenue of 142 million yuan (+17.44%) and a net profit of 25 million yuan (+268.13%) [6] - The company expects revenues of 599 million yuan, 759 million yuan, and 952 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 32.0%, 26.8%, and 25.4% [9] Growth Drivers - The company’s ultrasound bone knife product line is experiencing rapid growth, with over 50% increase in both shipment volume and sales value for the high-margin consumables [7] - The innovative spinal surgery robot and the JAZZ system are expected to create long-term competitive advantages, with the robot entering the "innovation channel" for expedited approval [8] - The U.S. market has become the largest market for the company’s subsidiary Implanet, with a revenue growth of 83.04% year-on-year [7]

Core Viewpoint - Despite strong performance with over 20% gains in two healthcare-themed funds managed by Guo Lan, the funds faced record net redemptions since inception [1][2]. Fund Performance - In Q3 2025, all three funds managed by Guo Lan significantly outperformed their respective benchmarks, with the China Europe Mingrui New Starting Fund achieving nearly 60% gains [2][9]. - The China Europe Healthcare Fund's stock allocation reached a historical high of 94.56% [2][3]. - The China Europe Healthcare Fund experienced a net redemption of 23.42 million shares in Q3, the highest since its inception, despite an increase in net asset value to 32.953 billion yuan [3][4]. Investment Strategy - The China Europe Healthcare Fund made its first investment in Haikang and increased holdings in Kanglong Chemical, Baili Tianheng, Kailai Ying, Tigermed, and Xinlitai [2][4]. - The China Europe Medical Innovation Fund significantly increased its position in Kanglong Chemical, while reducing stakes in several other companies [6][7]. - The China Europe Mingrui New Starting Fund diversified its investments, adding six new stocks, all of which saw price increases exceeding 100% during Q3 [9][10]. Market Outlook - Guo Lan remains optimistic about the investment value in innovative drugs, medical devices, and consumer healthcare, citing ongoing innovation and recovery in consumption as key drivers for the pharmaceutical industry [2][11]. - The report highlights the continued support for innovative drugs and the potential for new growth in the consumer healthcare sector due to demographic changes and policy support [12].

Investment Rating - The report maintains a "Recommended" rating for the company, with an expected revenue growth of 26.3% in 2025 and a corresponding net profit growth of 49.7% [4][5]. Core Insights - The company has achieved stable revenue growth, with a reported revenue of 23.188 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 14.85%. The net profit attributable to shareholders reached 5.751 billion yuan, up 24.50% year-on-year [1]. - The internationalization process is accelerating, highlighted by three overseas business development (BD) licensing agreements, including a collaboration with GSK worth up to 12 billion USD [2]. - Continuous innovation in research and development is evident, with new drug approvals and a robust pipeline of over 100 innovative products in clinical development [3]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported a revenue of 231.88 billion yuan, a net profit of 57.51 billion yuan, and a non-GAAP net profit of 55.89 billion yuan, showing significant year-on-year growth [1]. - The third quarter alone saw revenues of 74.27 billion yuan and a net profit of 13.01 billion yuan, reflecting a year-on-year increase of 12.72% and 9.53%, respectively [1]. Internationalization Efforts - The company has made significant strides in its internationalization efforts, including a partnership with GSK for the development of up to 12 innovative drugs, with an initial payment of 500 million USD [2]. - Additional licensing agreements include the overseas rights for HRS-1893 and the partial international market rights for a trastuzumab product, indicating a strong focus on global market expansion [2]. Research and Development - The company has successfully launched new products, including EZH2 inhibitors and other innovative drugs, while also having eight new drug applications accepted [3]. - The company presented 46 research results in oncology at the 2025 ESMO annual meeting, showcasing its commitment to advancing cancer treatment [3]. - A total of 24 first-class innovative drugs and 5 second-class new drugs have been approved for marketing in China, with over 400 clinical trials ongoing [3].

Core Insights - The company reported revenue of 2.381 billion yuan (+18.29% YoY) and a net profit of 509 million yuan (+12.90% YoY) for the first three quarters of 2025, aligning with expectations [1] - The company is experiencing stable revenue performance in Q3 2025, with a quarterly revenue of 815 million yuan (+20.12% YoY), despite short-term disruptions from centralized procurement in regions like Heilongjiang [1] - The company is enhancing its overseas localization efforts and expects significant contributions from the acquisition of CME, with the Thai manufacturing center expected to commence production by year-end [1] Revenue and Profitability - The gross margin for the first three quarters of 2025 was 64.5% (-3.1 percentage points YoY), primarily due to intensified competition from centralized procurement and price reductions on certain products [1] - The net profit margin for the same period was 21.4% (-1.0 percentage point YoY), supported by steady overseas business development and cost-reduction initiatives [1] Innovation and R&D - R&D expenses accounted for 5.6% of revenue during the first three quarters of 2025, remaining stable YoY, indicating a commitment to innovation and product development [2] - The company is expected to see steady growth in the sales of its visualization products and anticipates the interventional oncology sector to become a key growth area in the future [2] Profit Forecast and Valuation - The profit forecasts for 2025 and 2026 remain unchanged, with corresponding P/E ratios of 23x and 19x [3] - The target price is maintained at 102.0 yuan, representing a 17% upside, with target P/E ratios of 26x and 22x for 2025 and 2026 respectively [3]